Audax, Together with Management has invested in LABORIE Medical Technologies

Audax, Together with Management has invested in LABORIE Medical Technologies

The Company: Laborie Medical Technologies, Inc. (“LABORIE”), based in Toronto, Ontario, is a leading global provider of urodynamic testing equipment and consumables for urinary incontinence. Laborie supplies physician offices, hospitals and mobile providers on six continents.

The Deal: Audax Private Equity, together with management, has invested in Laborie. Oliver, Lipman & Associates advised Laborie. Bank of Montreal provided financing to support the investment.

The Thesis: Invest behind a leading global manufacturer and supplier of medical testing equipment and consumables with exceptional brand recognition and industry-leading technologies. Audax will work with management to execute a growth strategy focused on business transition and professionalization, expanding into adjacent markets, and strategic add-on acquisitions.

LTM Platform Investments:

audax-investment

Audax Investment Criteria: Audax private equity invests over $2.4 billion of equity capital in control acquisitions of lower-middle market companies across a select group of industries. We pursue a Buy & Build strategy that transforms small businesses into strategic assets. This involves buying platform companies that are niche market leaders in our areas of expertise and combining them with a series of strategic add-on acquisitions that catalyzes organic growth. To supplement our Buy& Build approach, we pursue numerous execution-oriented strategies including business professionalization, operational improvement and organic revenue growth to further generate value.

COOKIE SETTINGS

We use cookies to provide you with an optimal website experience. This includes cookies that are necessary for the operation of the site as well as cookies that are only used for anonymous statistical purposes. You can decide for yourself if you want to allow cookies for anonymous statistical purposes. If yes, please click 'Consent' instead of 'Decline'. Further information can be found in our privacy policy